Business
Commercial Collaboration
Commercial Collaboration.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n23 July 2024\nGraft Polymer (UK) plc\n(\"Graft Polymer\" or the \"Company\")\n \nUpdate on collaboration with Awakn Life Sciences\n \nPatent Authority evaluations indicate promising path to U.S. patents being granted\n \n \nFurther to the investment and commercial collaboration with Awakn Life Sciences (\"Awakn\") announced on 18 July 2024, the Company wishes to highlight the details of an announcement made by Awakn after markets closed yesterday in Canada.\n \nAwakn's announcement relates to Graft Polymer's interest in the aminoindane new chemical entity (\"NCE\") series (the \"Aminoindane NCEs\"), a novel treatment under development targeting trauma related mental health disorders such as Post Traumatic Stress Disorder (PTSD).\n \nPTSD, for example, is thought to affect approximately 13[1] million adults in the USA and 20 million[2,3,4] in other key international markets. It is a growing and largely unresolved healthcare challenge.\n \nThe Aminoindane NCEs are small molecule empathogens that promote the release of serotonin, dopamine, and noradrenaline while blocking their reuptake.\n \nPatent status in key international markets\n \nIn May 2021 Awakn filed provisional patent applications covering the Aminoindane NCEs, their pharmaceutical compositions, and innovative treatment methods for substance use and mental health disorders. These patent applications are now progressing well across multiple jurisdictions:\n \n· The United States: The fast-tracked U.S. patent application, facilitated by the Patent Prosecution Highway (\"PPH\"), is under examination. Positive evaluations from the International Searching Authority (\"ISA\") indicate a promising path to a U.S. patent being granted.\n· Europe: The European patent application is pending, with substantive examination expected to begin soon. European patent counsel is optimistic about securing a granted patent, as claims were already deemed novel and inventive by a European Patent Office (\"EPO\") examiner during the international stage,\n· Canada: The Canadian patent application, pending examination, also holds strong prospects for a granted patent. The examination process in Canada can be expedited using the PPH, enhancing IP protection efficiency.\n \nProf. Da...